Moderna's Coronavirus Vaccine to Be Reviewed by FDA Advisory Committee on Dec. 17

Brian Orelli, PhD, The Motley Fool
·2-min read
Moderna's Coronavirus Vaccine to Be Reviewed by FDA Advisory Committee on Dec. 17

Moderna (NASDAQ: MRNA) reported complete data for its coronavirus vaccine candidate, mRNA-1273, today. It also submitted its application for emergency use authorization to the Food and Drug Administration (FDA). Investors will have to wait a few weeks to see what the agency thinks of the data package.